GH Research's 15min chart triggers KDJ Golden Cross, Bullish Marubozu signal.

According to GH Research's 15-minute chart, a KDJ Golden Cross and Bullish Marubozu formation occurred on September 3, 2025 at 12:15 PM. This indicates a shift in the momentum of the stock price towards the upside, suggesting a potential for further price appreciation. As buyers continue to dominate the market, it is likely that the bullish momentum will persist.

According to GH Research's 15-minute chart, a KDJ Golden Cross and Bullish Marubozu formation occurred on September 3, 2023 at 12:15 PM. This indicates a shift in the momentum of the stock price towards the upside, suggesting a potential for further price appreciation. As buyers continue to dominate the market, it is likely that the bullish momentum will persist.

Guardant Health, Inc. (NASDAQ:GH) is a precision oncology company that provides blood tests, data sets, and analytics in the United States and internationally. The company's portfolio includes Guardant360, Guardant360 LDT, and Guardant360 CDx, among others. With a market capitalization of $3.05 billion, GH has seen significant analyst attention, with 14 analysts rating the stock as a "moderate buy" [1].

The company's latest earnings report indicated a non-GAAP EPS of -$0.82, which beat analysts' expectations by $0.11, and revenue of $137.2 million, which exceeded expectations by $7.78 million [2]. Additionally, Guardant Health received its first commercial payor coverage for the Guardant Reveal test from Blue Cross and Blue Shield of Louisiana, further bolstering its market position [3].

The stock has seen a steady increase in institutional ownership, with notable insider transactions, including sales by Kumud Kalia and Meghan V Joyce [4]. Analysts have provided a range of price targets for the stock, with the average target being $56.87, suggesting a potential upside of 119.3% from the current price [5].

In conclusion, the recent technical formation on GH Research's chart, combined with the company's strong earnings and increasing institutional ownership, suggests a bullish outlook for Guardant Health stock. Investors should closely monitor the stock's performance and consider the potential for further price appreciation.

References:
[1] https://www.marketbeat.com/stocks/NASDAQ/GH/
[2] https://www.seekingalpha.com/article/4253717-guardant-health-inc-gh-2023-q2-results-earnings-call-transcript
[3] https://www.morningstar.com/news/guardant-health-inc-gh-stock-quote
[4] https://www.marketbeat.com/stocks/NASDAQ/GH/
[5] https://www.marketbeat.com/stocks/NASDAQ/GH/